PortfoliosLab logoPortfoliosLab logo
PLX vs. MU
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

PLX vs. MU - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Protalix BioTherapeutics, Inc. (PLX) and Micron Technology, Inc. (MU). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, PLX achieves a 8.89% return, which is significantly lower than MU's 278.41% return. Over the past 10 years, PLX has underperformed MU with an annualized return of -13.01%, while MU has yielded a comparatively higher 56.13% annualized return.


PLX

1D
-1.51%
1M
-7.98%
YTD
8.89%
6M
13.95%
1Y
22.50%
3Y*
-3.92%
5Y*
-1.74%
10Y*
-13.01%

MU

1D
1.45%
1M
87.28%
YTD
278.41%
6M
361.42%
1Y
958.34%
3Y*
150.98%
5Y*
67.58%
10Y*
56.13%
*Multi-year figures are annualized to reflect compound growth (CAGR)

PLX vs. MU - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
PLX
Protalix BioTherapeutics, Inc.
8.89%-4.26%5.62%29.93%64.72%-77.09%10.67%5.47%-52.96%48.58%
MU
Micron Technology, Inc.
278.41%240.24%-0.96%71.93%-45.93%24.21%39.79%69.49%-22.84%87.59%

Correlation

The correlation between PLX and MU is 0.15, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.15

Correlation (3Y)
Calculated over the trailing 3-year period

0.12

Correlation (5Y)
Calculated over the trailing 5-year period

0.12

Correlation (10Y)
Calculated over the trailing 10-year period

0.12

Correlation (All Time)
Calculated using the full available price history since May 18, 1998

0.12

Fundamentals

Market Cap

PLX:

$162.78M

MU:

$1.23T

EPS

PLX:

$0.19

MU:

$21.26

PE Ratio

PLX:

10.34

MU:

50.79

PS Ratio

PLX:

2.08

MU:

21.07

PB Ratio

PLX:

1.72

MU:

16.98

Total Revenue (TTM)

PLX:

$76.38M

MU:

$58.12B

Gross Profit (TTM)

PLX:

$53.44M

MU:

$33.96B

EBITDA (TTM)

PLX:

$20.91M

MU:

$25.99B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

PLX vs. MU — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PLX
PLX Risk / Return Rank: 5353
Overall Rank
PLX Sharpe Ratio Rank: 5353
Sharpe Ratio Rank
PLX Sortino Ratio Rank: 5252
Sortino Ratio Rank
PLX Omega Ratio Rank: 5252
Omega Ratio Rank
PLX Calmar Ratio Rank: 5454
Calmar Ratio Rank
PLX Martin Ratio Rank: 5252
Martin Ratio Rank

MU
MU Risk / Return Rank: 9999
Overall Rank
MU Sharpe Ratio Rank: 100100
Sharpe Ratio Rank
MU Sortino Ratio Rank: 9999
Sortino Ratio Rank
MU Omega Ratio Rank: 9999
Omega Ratio Rank
MU Calmar Ratio Rank: 100100
Calmar Ratio Rank
MU Martin Ratio Rank: 100100
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PLX vs. MU - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Protalix BioTherapeutics, Inc. (PLX) and Micron Technology, Inc. (MU). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


PLXMUDifference
Sharpe ratioReturn per unit of total volatility

-14.35

Sortino ratioReturn per unit of downside risk

-6.40

Omega ratioGain probability vs. loss probability

1.12

1.94

-0.82

Calmar ratioReturn relative to maximum drawdown

0.57

31.98

-31.41

Martin ratioReturn relative to average drawdown

1.07

126.47

-125.40

PLX vs. MU - Sharpe Ratio Comparison

The current PLX Sharpe Ratio is 0.34, which is lower than the MU Sharpe Ratio of 14.69. The chart below compares the historical Sharpe Ratios of PLX and MU, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


PLXMUDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.34

14.69

-14.35

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.03

1.30

-1.33

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.16

1.13

-1.30

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.07

0.31

-0.38

Drawdowns

PLX vs. MU - Drawdown Comparison

The maximum PLX drawdown since its inception was -99.91%, roughly equal to the maximum MU drawdown of -98.25%. Use the drawdown chart below to compare losses from any high point for PLX and MU.


Loading charts...

Drawdown Indicators


PLXMUDifference

Max Drawdown

Largest peak-to-trough decline

-99.91%

-98.25%

-1.66%

Max Drawdown (1Y)

Largest decline over 1 year

-39.68%

-30.28%

-9.40%

Max Drawdown (3Y)

Largest decline over 3 years

-62.96%

-57.63%

-5.33%

Max Drawdown (5Y)

Largest decline over 5 years

-73.21%

-57.63%

-15.58%

Max Drawdown (10Y)

Largest decline over 10 years

-94.37%

-57.63%

-36.74%

Current Drawdown

Current decline from peak

-99.78%

0.00%

-99.78%

Average Drawdown

Average peak-to-trough decline

-93.66%

-58.20%

-35.46%

Ulcer Index

Depth and duration of drawdowns from previous peaks

21.01%

7.64%

+13.37%

Volatility

PLX vs. MU - Volatility Comparison

The current volatility for Protalix BioTherapeutics, Inc. (PLX) is 13.87%, while Micron Technology, Inc. (MU) has a volatility of 28.51%. This indicates that PLX experiences smaller price fluctuations and is considered to be less risky than MU based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


PLXMUDifference

Volatility (1M)

Calculated over the trailing 1-month period

13.87%

28.51%

-14.64%

Volatility (6M)

Calculated over the trailing 6-month period

44.36%

53.48%

-9.12%

Volatility (1Y)

Calculated over the trailing 1-year period

66.69%

66.00%

+0.69%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

67.72%

52.31%

+15.41%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

79.33%

49.66%

+29.67%

Dividends

PLX vs. MU - Dividend Comparison

PLX has not paid dividends to shareholders, while MU's dividend yield for the trailing twelve months is around 0.05%.


PositionTTM20252024202320222021
MU
Micron Technology, Inc.
0.05%0.16%0.55%0.54%0.89%0.21%
PLX
Protalix BioTherapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%

Financials

PLX vs. MU - Financials Comparison

This section allows you to compare key financial metrics between Protalix BioTherapeutics, Inc. and Micron Technology, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00B10.00B15.00B20.00B20222023202420252026
33.75M
23.86B
(PLX) Total Revenue
(MU) Total Revenue
Values in USD except per share items

PLX vs. MU - Profitability Comparison

The chart below illustrates the profitability comparison between Protalix BioTherapeutics, Inc. and Micron Technology, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

-40.0%-20.0%0.0%20.0%40.0%60.0%80.0%20222023202420252026
87.8%
74.4%
Portfolio components
PLX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Protalix BioTherapeutics, Inc. reported a gross profit of 29.62M and revenue of 33.75M. Therefore, the gross margin over that period was 87.8%.

MU - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Micron Technology, Inc. reported a gross profit of 17.75B and revenue of 23.86B. Therefore, the gross margin over that period was 74.4%.

PLX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Protalix BioTherapeutics, Inc. reported an operating income of 21.15M and revenue of 33.75M, resulting in an operating margin of 62.7%.

MU - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Micron Technology, Inc. reported an operating income of 16.13B and revenue of 23.86B, resulting in an operating margin of 67.6%.

PLX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Protalix BioTherapeutics, Inc. reported a net income of 18.32M and revenue of 33.75M, resulting in a net margin of 54.3%.

MU - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Micron Technology, Inc. reported a net income of 13.79B and revenue of 23.86B, resulting in a net margin of 57.8%.


Frequently Asked Questions


PLX and MU have a correlation of 0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

MU has higher volatility (28.51%) compared to PLX (13.87%). In terms of maximum drawdown, PLX dropped -99.91% vs MU's -98.25%.

MU currently has the higher Sharpe Ratio (14.69 vs 0.34), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for PLX and MU

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer